Recordati SpAMIL:REC +0.88%96 EBITDA Margin % is 38.85% as of Mar. 2026, which is 13% above its 10-year median of 34.52. GuruFocus rates MIL:REC with a GF Score™ of 96/100 and a GF Value™ of €60.63 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Recordati SpA ranks better than 90.37% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Recordati SpA's EBITDA for the
three
months ended in Mar. 2026 was €277 Mil. Recordati SpA's Revenue for the
three
months ended in Mar. 2026 was €713 Mil. Therefore, Recordati SpA's EBITDA margin for the quarter that ended in Mar. 2026 was 38.85%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Recordati SpA EBITDA Margin % Related Terms
Recordati SpA EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Recordati SpA's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:REC vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Recordati SpA's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Recordati SpA's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recordati SpA (MIL:REC) has a EBITDA Margin % of 38.85% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Recordati SpA and its competitors. This is 13% above median its historical median of 34.52. Over the past decade, Recordati SpA's EBITDA Margin % has ranged from 30.18 to 39.12. According to the industry distribution chart, Recordati SpA ranks #92 out of 955 companies in the Drug Manufacturers industry, placing it in the top 9.6%.
Is Recordati SpA's EBITDA Margin % too high?
Recordati SpA's current EBITDA Margin % of 38.85% is 13% above median its 10-year median of 34.52. Over the past 10 years, this metric has ranged from a low of 30.18 to a high of 39.12. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Recordati SpA's value of 38.85% is 213.6% above this industry median. Based on the distribution chart, Recordati SpA ranks #92 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Recordati SpA has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #92 out of 955 companies for EBITDA Margin %. This places Recordati SpA in the top 10% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Recordati SpA's value of 38.85% is 213.6% above this benchmark. Historically, Recordati SpA's own EBITDA Margin % has ranged from 30.18 to 39.12 over the past decade. While the company's 10-year median is 34.52 vs. the industry median of 12.39, Recordati SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current EBITDA Margin % of 38.85% is 213.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Recordati SpA and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current EBITDA Margin % is 38.85%, which is 13% above median its own 10-year median of 34.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €60.63, compared to a current price of €51.55 — trading 15% below its estimated fair value. The current EBITDA Margin % is 38.85%, which is 13% above median its 10-year median of 34.52 and 213.6% above the Drug Manufacturers industry median of 12.39. Recordati SpA's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current EBITDA Margin % is 38.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MIL:REC) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of €51.55 is trading 15% below its estimated GF Value™ of €60.63.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MIL:REC:
EBITDA Margin %: 38.85% (13% above median its 10-year median of 34.52)
GF Value™: €60.63 vs. price of €51.55 (15% below fair value)
Industry Position: 213.6% above the Drug Manufacturers median (#92 of 955)
No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
96GF Score
Get the complete analysis for MIL:REC
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:REC has been successfully added to your 
